Arabic Arabic English English French French German German
dark

Harbour BioMed Reports 2021 Interim Results

Harbour BioMed, a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, reported its interim results for the six months ended June 30, 2021, and provided key business updates. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Vesto and Oldham Global Announce a Strategic Partnership To Provide Alternative Pharmaceutical Financing

Next Post

Verona Pharma to Present at H.C. Wainwright 23rd Annual Global Investment Conference

Related Posts
Total
0
Share